HOME >> BIOLOGY >> NEWS
PATH Malaria Vaccine Initiative announces partnership to develop novel malaria vaccine

Bethesda, MD, USA (December 14, 2006) In a move that promises to expand the types of malaria vaccine candidates in clinical development, the PATH Malaria Vaccine Initiative (MVI) today announced a new partnership with Sanaria Inc., a Maryland company, to accelerate development of a unique malaria vaccine candidate.

Supported by a $29.3 million grant to PATH from the Bill & Melinda Gates Foundation, this strategic partnership will focus on the development and manufacture of Sanaria's malaria vaccine candidateone that uses a novel, whole-parasite approach to preventing infection from the most deadly malaria parasite, Plasmodium falciparum. MVI and Sanaria will move quickly to conduct an initial safety and test-of-concept trial of the Sanaria candidate among volunteers in the United States.

"Close to one million children die of malaria each year," said Dr. Melinda Moree, Director of MVI. "With this support, we can examine another promising malaria vaccine technology and bring the field closer to delivering a safe, effective, and affordable pediatric malaria vaccine to at-risk communities in Africa."

Of the more than one million people who die of malaria every year, most of them are African children under five years old. Hundreds of millions more people suffer the effects of the mosquito-borne, parasitic disease each year. Scientists have been working for years to develop a preventive malaria vaccine and have recently demonstrated that such a vaccine is possible.

While the approach of much malaria vaccine research and development has centered on using one or more components of the malaria parasite that the human immune system can recognize, Sanaria is focused on using an attenuated, or weakened, form of the whole parasite. The idea is that when this attenuated parasite is given to individuals, they will become immune to malaria but will not get sick. This is the first vaccine candidate of its kind in the MVI portfolio.<
'"/>


14-Dec-2006


Page: 1 2

Related biology news :

1. Malaria -- Effective insecticide-repellent synergy against mosquito vectors
2. Malaria-resistant mosquitoes battle disease with molecular warhead
3. Malaria and Epstein-Barr virus linked to pediatric cancer in Africa
4. Malaria in pregnancy: What can the social sciences contribute?
5. Malaria: The right vaccine in the right place?
6. 20 Years of Malaria Research: Outcomes and Perspectives
7. Malaria poses additional risks for first-time mothers
8. Malaria drug may treat metabolic syndromes many symptoms
9. Malaria: Efficacy of monotherapies in Cameroon
10. Malaria, potato famine pathogen share surprising trait
11. Malaria parasite impairs key immune system cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/15/2019)... ... August 15, 2019 , ... Deep Science Ventures ... Food and Agriculture practice, a new unit dedicated to building 100 companies over the ... raw materials and supply chains. , Deep Science Ventures was founded to create ...
(Date:8/14/2019)... ... ... Join Jonathan Riek, PhD, VP, Musculoskeletal & Metabolic Imaging, BioTel Research ... EDT to learn about two common imaging methods in NAFLD/NASH to aid with early ... diffuse liver disease, with a worldwide prevalence of 20-46 percent. NAFLD can be subdivided ...
(Date:8/9/2019)... ... , ... With a demand in healthcare to lower unneeded emergency room visits ... centers (UCC) in the coming years, according to a new report on the industry ... Centers , is a detailed look at the current state of these healthcare outlets, ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... , ... June 10, 2019 , ... ... and technology in an upcoming episode, scheduled to broadcast 4Q/2019. Check your local ... Group) and will educate viewers about how its technology facilitates laboratories to improve ...
(Date:6/11/2019)... Md. and ROANOKE, Va. (PRWEB) , ... June ... ... care optimized for microlearning engagement, and Carilion Clinic, a national leader in opioid ... the latest in virtual care. , Mytonomy recently deployed its virtual ...
(Date:6/11/2019)... N.C. (PRWEB) , ... June 11, 2019 , ... ... extracellular vesicles derived from human mesenchymal stem cells (MSC-EV) are able to incorporate ... cloning ability. In a test on mice, MSC-EVs also increased the cells’ ability ...
(Date:5/31/2019)... ... , ... For many years, the primary forms of cancer treatment have been ... in immuno-oncology have led to the advent of Chimeric Antigen Receptor T (CAR T) ... known as “CARs”. The CAR enables the final product to produce chemicals in the ...
Breaking Biology Technology:
Cached News: